Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas

European Journal of Cancer

Volumn 44, Issue 15, 2008, Pages 2312-2318

  Granci, Virginie ^a,c   Bibeau, Frédéric ^b,c   Kramar, Andrew ^b   Boissière Michot, Florence ^b   Thézénas, Simon ^b   Thirion, Agnès ^b   Gongora, Céline ^a   Martineau, Pierre ^a   Rio, Maguy Del ^a   Ychou, Marc ^b  

^a INSERM   (France)

^b CENTRE VAL D AURELLE   (France)

^c NONE

Author keywords

5 FU; Apoptosis; Chemo resistance; Colorectal cancer; Immuno histochemistry; TRAIL receptors; TRAIL R1; TRAIL R3

Indexed keywords

CAPECITABINE; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FLUOROURACIL; FOLINIC ACID; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CARCINOMA; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PREDICTION AND FORECASTING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR DECOY RECEPTORS;

EID: 53249109351     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.06.042     Document Type: Article

References (33)

1. Pan G., O'Rourke K., Chinnaiyan A.M., et al. The receptor for the cytotoxic ligand TRAIL. Science 276 (1997) 111-113
2. Ashkenazi A., Pai R.C., Fong S., et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104 (1999) 155-162
3. Gliniak B., and Le T. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res 59 (1999) 6153-6158
4. de Vries E.G., Gietema J.A., and de Jong S. Tumor necrosis factor-related apoptosis-inducing ligand pathway and its therapeutic implications. Clin Cancer Res 12 (2006) 2390-2393
5. Duiker E.W., Mom C.H., de Jong S., et al. The clinical trail of TRAIL. Eur J Cancer 42 (2006) 2233-2240
6. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New Engl J Med 351 (2004) 337-345
7. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med 350 (2004) 2335-2342
8. Naka T., Sugamura K., Hylander B.L., et al. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res 62 (2002) 5800-5806
9. Shimoyama S., Mochizuki Y., Kusada O., et al. Supra-additive antitumor activity of 5FU with tumor necrosis factor-related apoptosis-inducing ligand on gastric and colon cancers in vitro. Int J Oncol 21 (2002) 643-648
10. Arts H.J., de Jong S., Hollema H., et al. Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma. Gynecol Oncol 92 (2004) 794-800
11. Bernard D., Quatannens B., Vandenbunder B., et al. Rel/NF-kappaB transcription factors protect against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by up-regulating the TRAIL decoy receptor DcR1. J Biol Chem 276 (2001) 27322-27328
12. Sanlioglu A.D., Dirice E., Aydin C., et al. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer 5 (2005) 54
13. Miller A.B., Hoogstraten B., Staquet M., et al. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
14. van Geelen C.M., Westra J.L., de Vries E.G., et al. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. J Clin Oncol 24 (2006) 4998-5004
15. Hueber A., Aduckathil S., Kociok N., et al. Apoptosis-mediating receptor-ligand systems in human retinal pigment epithelial cells. Graefes Arch Clin Exp Ophthalmol 240 (2002) 551-556
16. Sanlioglu A.D., Dirice E., Elpek O., et al. High levels of endogenous tumor necrosis factor-related apoptosis-inducing ligand expression correlate with increased cell death in human pancreas. Pancreas 36 (2008) 385-393
17. Sanlioglu A.D., Korcum A.F., Pestereli E., et al. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma. Int J Radiat Oncol Biol Phys 69 (2007) 716-723
18. Schon M.P., Wienrich B.G., Drewniok C., et al. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Invest Dermatol 122 (2004) 1266-1276
19. Mundt B., Wirth T., Zender L., et al. Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake. Gut 54 (2005) 1590-1596
20. Strater J., Hinz U., Walczak H., et al. Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin Cancer Res 8 (2002) 3734-3740
21. Reed J.C. Apoptosis-targeted therapies for cancer. Cancer Cell 3 1 (2003) 17-22
22. Reesink-Peters N., Hougardy B.M., van den Heuvel F.A., et al. Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study. Gynecol Oncol 96 (2005) 705-713
23. Younes M., Georgakis G.V., Rahmani M., et al. Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma. Eur J Cancer 42 (2006) 542-547
24. Riccioni R., Pasquini L., Mariani G., et al. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica 90 (2005) 612-624
25. Merino D., Lalaoui N., Morizot A., et al. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 26 (2006) 7046-7055
26. Secchiero P., Gonelli A., Carnevale E., et al. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 107 (2003) 2250-2256
27. Sheridan J.P., Marsters S.A., Pitti R.M., et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277 (1997) 818-821
28. Wang S., and El-Deiry W.S. Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. Cancer Res 64 (2004) 6666-6672
29. Chan F.K. Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling. Cytokine 37 (2007) 101-107
30. Clancy L., Mruk K., Archer K., et al. Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci USA 102 (2005) 18099-180104
31. Benatti P., Gafa R., Barana D., et al. Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res 11 (2005) 8332-8340
32. Etienne M.C., Chazal M., Laurent-Puig P., et al. Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J Clin Oncol 20 (2002) 2832-2843
33. Pukac L., Kanakaraj P., Humphreys R., et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Brit J Cancer 92 (2005) 1430-1441